To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions

Inclusion criteria

• Males or non-pregnant females aged 18 months or older.
• Must have a secondarily infected traumatic skin lesion such as a laceration, sutured wound, or abrasion.
• Must have a positive baseline culture for S. aureus and/or S. pyogenes from a sample taken from the secondarily infected traumatic skin lesion.
• Must have a positive Gram stain or Wright stain for confirmation of white blood cells in the pus/exudate from the secondarily infected traumatic skin lesion.
• Must have a Skin Infection Rating Scale (SIRS) total score for the secondarily infected traumatic skin lesion of at least 8 at baseline.
• Must be willing and able to understand and comply with the requirements of the study, apply the medication as instructed, and be able to complete the study.
• Must be in general good health and free from any clinically significant disease, other than secondarily infected traumatic skin lesion(s), that might interfere with the study evaluations.

Exclusion criteria

• Subjects who are pregnant, breastfeeding, or planning a pregnancy within the period of their study participation.
• Presence of any dermatological disorder that may interfere with evaluation of the subject's secondarily infected traumatic skin lesion(s).
• Presence of bacterial skin infection that, because of depth or severity, could not be appropriately treated with a topical antibiotic.
• Presence of secondarily infected bite or puncture wound.
• Presence of systemic signs or symptoms of infection (fever defined as an oral temperature greater than 101°F or 38.3°C).
• Requirement for surgical intervention for treatment of the infection prior to study entry.
• Presence of cutaneous herpes simplex infections.
• Use of any topical corticosteroid, topical antibiotic, or topical antifungal, on the secondarily infected target lesion, within 48 hours prior to Visit 1/Day 1.
• Use of systemic antibiotics or systemic corticosteroids within 7 days of Visit 1/Day 1.
• Primary or secondary immunodeficiency.
• Diagnosed Diabetes Mellitus (controlled or uncontrolled).
• Any uncontrolled, chronic or serious disease or medical condition that would prevent participation in a clinical trial, or, in judgment of the investigator, would put the subject at undue risk or might confound the study assessments.
• History of hypersensitivity or allergy to mupirocin and/or any ingredient in the study medication.
• Subject consumes excessive alcohol, abuses drugs, or has a condition that could compromise the subject's ability to comply with study requirements.
• Subjects who, in the opinion of the investigator, are unlikely to be able to follow the restrictions of the protocol and complete the study.